Obesity drug sales help Novo Nordisk beat expectations
Sales of Novo Nordisk’s obesity drug, Wegovy, rose by more than 50 per cent last year, helping the Danish drugmaker beat revenue expectations. The company on Wednesday reported that net sales increased by 26 per cent year on year in 2024 to DKr290bn ($40bn),
Surgical patients may still have leftovers in their system even after a standard fast, potentially increasing the chance of a ...
Alexandra Sowa's new book The Ozempic Revolution is intended to be the "first comprehensive user guide" to GLP-1 drugs like ...
The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating." ...
Regulators have approved the drug as a treatment for weight loss, Type 2 diabetes and lowering the risk of heart attacks and ...
Physician–scientists at the University of Utah's John A. Moran Eye Center have published an investigatory review of nine ...
The Cleveland Clinic also warns against buying into the “nature’s Ozempic” hype, but says the supplement could also aid in ...
Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...
Several years ago, a little-known drug named Ozempic—previously used only to treat diabetes—emerged as a promising new ...
Actress and comedian Amy Schumer said she took Ozempic three years ago and quickly lost 30 lbs. However, she quit the ...
Ozempic (semaglutide) is a brand-name drug prescribed to treat certain conditions, such as type 2 diabetes. Ozempic has interactions with some other drugs, such as insulin, and certain ...
Salon on MSN11d
Scientists find Ozempic may treat cancer, Alzheimer's and more. Is it hype or truly a "wonder drug?"Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...
GLP-1 drugs mimic a hormone that sends the brain signals of fullness. Researchers theorize that the drugs could work the same ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback